24/7 Market News Snapshot 13 March, 2025 – Cellectar Biosciences INC NEW (NASDAQ:CLRB)

March 13, 2025

DENVER, Colo., 13 March, 2025 (247marketnews.com) – (NASDAQ:CLRB) are discussed in this article.
Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical innovator, is navigating a challenging pre-market environment with its stock currently at $0.290, an 8.40% drop from the previous close of $0.317. The trading volume has surged to 9.35 million shares, suggesting heightened investor activity amidst prevailing bearish sentiment. This downward trend has led to a focus on potential resistance levels around the previous close, prompting traders to carefully monitor support levels that may foretell further declines.

Despite the stock’s current challenges, Cellectar is making significant advancements in its therapeutic pipeline, particularly with iopofosine I 131, a novel treatment targeting Waldenström macroglobulinemia (WM). The company recently engaged in a constructive meeting with the U.S. Food and Drug Administration (FDA), establishing a clear regulatory path toward potential accelerated approval of this promising radiotherapeutic agent. Cellectar is gearing up to initiate a randomized, controlled trial, planning to enroll 100 patients per treatment arm to support the approval process.

James Caruso, President and CEO, emphasized the strategic importance of 2024, underscoring the efficacy and safety demonstrated by iopofosine I 131 for relapsed/refractory WM. Caruso also highlighted the opportunities for collaborations that could provide attractive avenues for non-dilutive funding.

Furthermore, Cellectar is advancing two additional radioconjugate assets with plans for a Phase 1b/2a dose-finding study of CLR 121125, targeting triple-negative breast cancer, along with an impending IND application for CLR 121225, geared toward solid tumors.

The company reported a robust cash position of $23.3 million as of December 31, 2024, a considerable increase from the prior year. With a strong financial foundation and dedicated focus on innovative cancer therapies, Cellectar Biosciences is well-positioned for future growth in the oncology landscape.

Related news for (CLRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.